Figure 2.

Management of atrial fibrillation in patients treated with ibrutinib. *Notable drug interactions with ibrutinib include diltiazem, verapamil, and amiodarone (CYP3A4 inhibitors) and amiodarone (P-glycoprotein). ^#1 point each for a history of congestive heart failure, hypertension, diabetes mellitus, or vascular disease, age 65 to 74 years, or female sex and 2 points each for age ≥75 years or a history of stroke. ^$Discuss risk of thromboembolic events with patient. ^Possible options include venetoclax with or without rituximab, idelalisib, and duvelisib.